Ann: Kazia releases preliminary Cantrixil Phase I data, page-3

First 3 Last

Share
Profile

Follow
onesurfed

2,073 Posts.

443

19/06/18

08:55

Post #: 33786015
Share

Originally posted by qqqqqqqqq ↑

The phase I study of Cantrixil commenced in December 2016 at five centres in the United States and Australia. It is designed in two parts: a dose escalation component (Part A), which seeks to understand the safety profile of the drug and to determine the maximum tolerated dose (MTD), and a dose expansion cohort (Part B), which seeks to explore initial signals of efficacy. Part A is expected to enroll between 3 and 42 patients, and Part B is expected to enroll 12 patients. The study is registered with clinicaltrials.gov as NCT02903771.
At the present time, the study has enrolled 10 patients in Part A. In general, the drug has encountered few dose-limiting toxicities and, as a result, most dosing cohorts have only required enrolment of a single patient, in line with the trial protocol, which has allowed the study to progress with a number of patients towards the lower extent of the forecast range.
Of the 10 patients recruited to date, 2 were withdrawn from the study prior to receiving treatment, generally on grounds of disease progression, reflecting the severity of this patient population. 3 of 5 patients evaluable for efficacy thus far have achieved ‘stable disease’ (SD) per RECIST criteria after 2 cycles of Cantrixil monotherapy. One patient demonstrated a ‘partial response’ (PR) after receiving Cantrixil in combination with chemotherapy. 3 patients have so far completed the full twenty-four weeks of dosing allowed for in the protocol.
The Data Monitoring Committee has recommended that additional patients should be enrolled to more fully understand the safety profile and to definitively determine the maximum tolerated dose, and the company has therefore continued Part A accordingly. It is now expected that Part A will conclude in the third calendar quarter of 2018, at which time Part B will commence. The Company expects to provide comprehensive data once Part A is complete.

Expand

You have anything original to say, or are you just posting to stir the pot? I'd say what I feel, but that would get me banned for another month.

KZA Price at posting: 61.5¢ Sentiment: Buy Disclosure: Held
4 Upvote

0 Great analysis

Reply

Top Stories

3DA

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

MKT

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

BIO

Biome reaches intellectual property milestone in strain development program

IR1

Iris Metals jumps +22% as NASDAQ's Stardust probes economics behind possible offtake

Trump is President Again: What Does This Mean for Crypto?

There are more pages in this discussion • 121 more messages in this thread...

First 3 Last

Add KZA (ASX) to my watchlist

Ann: Kazia releases preliminary Cantrixil Phase I data, page-3

Top Stories

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Biome reaches intellectual property milestone in strain development program

Iris Metals jumps +22% as NASDAQ's Stardust probes economics behind possible offtake

Trump is President Again: What Does This Mean for Crypto?

Featured News